REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND–(Marketwire – May 3, 2010) – Kerecis, the emerging tissue-regeneration company, has appointed Dr. Gudmundur Gudmundsson as vice president of science and technology.
Dr. Gudmundsson has extensive experience successfully leading large-scale live science development projects. Before joining the company, he spent 11 years in various positions for Decode Genetics including six years as project leader and senior research scientist studying cardiovascular and blood-vessel diseases. He also spent five years as alliance director, managing liaisons with pharmaceutical companies such as Hoffmann-La Roche, Ltd. and Merck & Co. Inc.
Dr. Gudmundsson received his master’s in biotechnology from Worcester Polytechnic Institute and his doctorate in molecular biology from the University of Southern California. He will be based in the company’s Reykjavik, Iceland, office.
Kerecis is involved in the research, development and production of tissue-regeneration products that can be used in reconstructive, soft- and hard-tissue surgical procedures. For regulatory purposes, the company’s technology is classified as a medical device. The patent-pending Kerecis technology is currently in the development stage. Kerecis received its start-up financing round in December 2009. The Kerecis team consists of experienced executives with proven track records in the development of medical-device businesses, in clinical development and in the protection of intellectual property.
Gudmundur F. Sigurjonsson, Kerecis founder and CEO: “Dr. Gudmundsson’s expertise and networks will immediately benefit our company’s tissue-regeneration development programs. With his appointment we have a complete material-development, pre-clinical and clinical-development organization.”
Kerecis ehf is a recently incorporated company founded to develop novel tissue-regeneration technologies based on proprietary fish-derived protein technologies.
For further information, contact:
Gudmundur F. Sigurjonsson
Founder and CEO, Kerecis
Phone (Iceland) +354 8494960
(U.S.) (703) 879-6535